Abstract
This research investigates the effects of cefaclor (CCL), a 3-cephem antibiotic, on platelet aggregation induced by various stimulants including PAF, ADP, collagen, endotoxin, and thrombin. Using guinea pig platelet-rich plasma and washed platelets, the study found that CCL inhibits aggregation triggered by PAF, ADP, and thrombin at concentrations of 300 µg/ml or higher. While CCL also inhibited collagen-induced aggregation and prolonged lag times, it had no effect on endotoxin-induced aggregation. Notably, CCL did not interfere with the intracellular Ca²⁺ increase produced by these stimulants, suggesting its inhibitory mechanism involves blocking fibrinogen binding to the glycoprotein IIb/IIIa complex rather than disrupting internal signaling.
Introduction
β-lactam antibiotics, such as penicillins and cephalosporins, are essential clinical tools but are occasionally associated with bleeding tendencies in patients. While traditionally attributed to Vitamin K metabolism interference, this study explores whether these drugs directly impair platelet function. The researchers focused on Cefaclor (CCL), an oral cephalosporin, and its interaction with Platelet Activating Factor (PAF)—a potent signaling molecule involved in inflammation and allergy.
Methodology and Measurement
The study utilized blood from male Hartley guinea pigs to prepare platelet-rich plasma (PRP) and washed platelets. Platelet aggregation was measured using the Born method of aggregometry, which tracks changes in light transmission as platelets clump together. Key parameters for analysis include the maximum aggregation percentage and the "lag time," which is the delay before clumping begins.
PAF as a "Force Multiplier"
A key insight from the study is that PAF acts as a potent enhancer of other stimulants. Even at concentrations too low to cause significant clumping on its own, PAF significantly boosts the aggregation response caused by ADP or endotoxins.
Cefaclor's Inhibitory Mechanism
Cefaclor demonstrated a clear inhibitory effect on aggregation triggered by PAF, ADP, and Thrombin at concentrations of 300 µg/ml or higher. For collagen-induced clumping, CCL significantly increased the lag time and decreased the overall rate of aggregation.
One of the most important findings regarding the mechanism of action was that while CCL stopped platelets from sticking together, it did not stop the rise of intracellular calcium ($Ca^{2+}$). Since the calcium signal—a primary internal trigger for activation—remained intact while aggregation was blocked, the researchers concluded that the drug must interfere with the final step of the process: the physical binding of platelets to fibrinogen via surface glycoprotein IIb/IIIa (GPIIb/IIIa) receptors.
Conclusion
The inhibitory effects of Cefaclor were found to be roughly equivalent to Latamoxef (LMOX), another antibiotic known to affect platelets. By likely blocking the GPIIb/IIIa receptor complex, these antibiotics prevent the cross-linking necessary for clot formation. While these effects are clear in a laboratory setting, further research is needed to determine if therapeutic doses in humans reach the concentrations necessary to cause clinical platelet dysfunction.
Summary updated